Vnitřní lékařství 5/2021

HLAVNÍ TÉMA Osteoporóza u mužů: podceňovaná a neléčená | 283 / Vnitř Lék 2021; 67(5): 271–283 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 18. Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002; 87(8): 3656. 19. Shahinian VB, Kuo YF, Freeman JL et al. Risk of fracture after androgen deprivation for prostate cancer. Goodwin JS SO N Engl J Med. 2005; 352(2): 154. 20. Watts NB, Leslie WD, Foldes AJ, Miller PD. 2013 International Society for Clinical Den- sitometry Position Development Conference: Task Force on Normative Databases. J Clin Densitom. 2013; 16(4): 472–481. 21. Kanis JA, Oden A, Johansson H et al. FRAX((R)) and its applications to clinical practi- ce. Bone. 2009; 44: 734–743. 22. Stepan JJ, Vaculik J, Pavelka K et al. Hip fracture incidence from 1981 to 2009 in the Czech Republic as a basis of the country-specific FRAX model. Calcif Tissue Int. 2012; 90(5): 365–372. 23. Dent E, Morley JE, Cruz-Jentoft AJ et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. J Nutr Health Aging. 2018; 22(10): 1148–1161. 24. Harvey NC, Biver E, Kaufman JM et al. The role of calcium supplementation in heal- thy musculoskeletal ageing: An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Di- seases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporos Int. 2017; 28: 447–462. 25. Rizzoli R. Dairy products, yogurts, and bone health. Am J Clin Nutr 2014; 99(5 Suppl): 1256s–1262s. 26. Rizzoli R, Stevenson JC, Bauer JM et al. ESCEO Task Force. The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a con- sensus statement from the European Society for Clinical and Economic Aspects of Osteo­ porosis and Osteoarthritis (ESCEO). Maturitas. 2014; 79: 122–132. 27. Rizzoli R. Nutritional influence on bone: role of gut microbiota. Aging ClinExp Res. 2019; 31(6): 743–751. 28. Giustina A, Adler RA, Binkley N et al. Consensus statement from 2 nd international con- ference on controversies in vitamin D. Rev Endocr Metab Disord 2020; 21: 89–116. 29. Rochira V, Antonio L & Vanderschueren D. EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology 2018; 6: 272–285. 30. Kaufman JM, Reginster JY, Boonen S et al. Treatment of osteoporosis in men. Bone. 2013; 53: 134–144. 31. Sawka AM, Papaioannou A, Adachi JD et al. Does alendronate reduce the risk of fractu- re in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in wo- men. BMC Musculoskelet Disord. 2005; 6: 39. 32. Boonen S, Lorenc RS, Wenderoth D et al. Evidence for safety and efficacy of risedro- nate in men with osteoporosis over 4 years of treatment: results from the 2-year, open- -label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. Bone. 2012; 51: 383–388. 33. Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int. 2009; 29: 311–315. 34. Sato Y, Iwamoto J, Kanoko T et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Int Med. 2005; 165: 743–1748. 35. Lyles KW, Colón-Emeric CS, Magaziner JS, HORIZON Recurrent Fracture Trial, et al. Zo- ledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357: 1799–1809. 36. Boonen S, Orwoll E, Magaziner J, HORIZON Recurrent Fracture Trial, et al. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Ge- riatr Soc. 2011; 59: 2084–2090. 37. Boonen S, Reginster JY, Kaufman JM et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012; 367: 1714–1723. 38. Khan AA, Morrison A, Kendler DL et al. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom. 2017; 20(1): 8–24. 39. Genant HK, Libanati C, Engelke K et al. Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab. Bone. 2013; 56: 482–488. 40. Smith MR, Egerdie B, Hernández Toriz N. Denosumab HALT Prostate Cancer Study Group, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009; 361: 745–755. 41. Orwoll E, Teglbjærg CS, Langdahl BL et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012; 97: 3161–3169. 42. Langdahl BL, Teglbjærg CS, Ho PR et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab. 2015; 100: 1335–1342. 43. Tourdi E, Langdahl B, Cohen-Solal M et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 2017; 105: 11–17. 44. Orwoll ES, Scheele WH, Paul S et al. The effect of teriparatide (human parathyroid hormone (1–34)) therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18: 9–17. 45. Saag KG, Zanchetta JR, Devogelaer JP et al. Effects of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: 36-month results of a randomized, double- -blind, controlled trial. Arthritis Rheum. 2009; 60: 3346–3355. 46. Díez-Pérez A, Marin F, Eriksen EF et al. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis. Bone. 2019; 120: 1–8. KNIŽNÍ NOVINKA ŽÍLY, ŽILKY A VARIXY Peter Baláž Onemocnění žil patří k nejrozšířenějším poruchám, s nimiž se v průběhu života setkává většina z nás. Významným aspektem přitom je fakt, že kromě zdravotních komplikací a rizik jde pro mnohé z nás rovněž o problém estetický. Knižní publikace určená široké veřejnosti nenáročným a srozumitelným způsobem přibližuje vznik žilního onemoc- nění, vysvětluje rozdíl jednotlivých forem a popisuje možnosti prevence a léčby. Pomocí ilustrací, fotografií a jedno- duchého pochopitelného výkladu připraví čtenáře na to, co by měl očekávat v lékařské ordinaci, názorně vysvětlí rozdíly v jednotlivých léčebných metodách a hlavně ulehčí rozhodnutí o podstoupení zákroku, které mnozí z nás dlouho odkládají. Kniha obsahuje přehled všech dostupných metod léčby, od sklerotizace, laseru až po operační metody pokročilých forem žilního onemocnění. Maxdorf 2021, 92 str., barevné ilustrace, Formát: 130 x 200 mm, brožovaná, ISBN: 978-80-7345-692-4, Cena: 195 Kč